Dosing regimen and tolerability of methoxy polyethylene glycol-epoetin beta in Chinese dialysis patients.

Item

http://www.wikidata.org/entity/Q43525009

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Dosing regimen and tolerabilit ...... in Chinese dialysis patients.

@en

Dosing regimen and tolerabilit ...... in Chinese dialysis patients.

@nl

type

Item

label

Dosing regimen and tolerabilit ...... in Chinese dialysis patients.

@en

Dosing regimen and tolerabilit ...... in Chinese dialysis patients.

@nl

prefLabel

Dosing regimen and tolerabilit ...... in Chinese dialysis patients.

@en

Dosing regimen and tolerabilit ...... in Chinese dialysis patients.

@nl

P1476

Dosing regimen and tolerabilit ...... a in Chinese dialysis patients

@en

P2093

Bo Ying Choy

http://www.w3.org/2001/XMLSchema#string

Chik Cheung Vincent Chow

http://www.w3.org/2001/XMLSchema#string

Desmond Yh Yap

http://www.w3.org/2001/XMLSchema#string

Hon Lok Tang

http://www.w3.org/2001/XMLSchema#string

Man Fai Lam

http://www.w3.org/2001/XMLSchema#string

Ping Nam Wong

http://www.w3.org/2001/XMLSchema#string

Terence Yip

http://www.w3.org/2001/XMLSchema#string

P2860

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.

Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia.

Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.

History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients.

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.

Hemoglobin variability and mortality in ESRD.

Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study.

P304

533-538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/NEP.12105

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tak Mao Chan

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23714233

http://www.w3.org/2001/XMLSchema#string

P921

renal dialysis